ArticleBMC cancer2026
Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUrothelial carcinoma (UC) is a prevalent malignancy that shows higher incidence in males but reportedly poorer outcomes in females. Among molecular subtypes, the basal/squamous (Ba/Sq) subtype is associated with poor prognosis and therapeutic resistance. Androgen receptor (AR) signaling has been implicated in UC pathogenesis, but its precise role in the Ba/Sq subtype remains unclear.
methodsJ82 cells stably expressing AR (J82-FLAG-AR) were established by retroviral transduction. Gene and protein expression were assessed by quantitative reverse transcription PCR (RT-qPCR) and Western blotting following dihydrotestosterone (DHT) treatment. To test AR-dependency, J82-FLAG-AR cells were co-treated with DHT and the AR antagonist enzalutamide (10 µM) for 24 h. To test p21 dependency of DHT-induced growth suppression, J82-FLAG-AR cells were transfected with siControl or siP21 (50 nM) followed by DHT treatment, with proliferation assessed by WST-8 assay. Co-immunoprecipitation was used to examine AR-enhancer of zeste homolog 2 (EZH2) interaction.
resultsAR expression in J82 cells was associated with reduced CLDN1 and CLDN4 (epithelial markers), increased GATA3 (luminal marker), and increased CDKN1A (p21) expression at both mRNA and protein levels following DHT stimulation. DHT treatment suppressed proliferation of J82-FLAG-AR cells. Co-immunoprecipitation demonstrated AR-EZH2 interaction. Combined DHT and EZH2 inhibitor (GSK126) treatment further increased p21 mRNA but did not produce additional antiproliferative effect. Pharmacological AR antagonism with enzalutamide attenuated DHT-induced p21 mRNA induction in a DHT-dose-dependent manner, consistent with competitive AR antagonism. siP21-mediated p21 knockdown abolished the DHT-induced suppression of proliferation observed in siControl-transfected cells (siRNA × DHT interaction, P = 0.047).
conclusionsIn the Ba/Sq UC cell line J82, AR-dependent p21 induction contributes to DHT-induced suppression of proliferation, together with altered epithelial and luminal marker transcription. These observations support a p21-mediated, AR-dependent growth-restraining role for AR signaling in this subtype.
Indexed as
Identifiers
42919251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.